Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

If You Can Handle the Bumpy Ride, Workhorse Group Is a Buy for the Long Term

By Chris Lau, InvestorPlace Contributor

A short float of 30% will add to the volatility in shares of Workhorse in the near-term, while the long-term prospects look great.

Why Palantir’s Long-Term Prospects Are Brighter than Ever

By Chris Lau, InvestorPlace Contributor

PLTR stock is on a big jump in the last month. Investors who want to take a position should wait for the stock price to settle.

Here’s What to Do If Nio Stock Starts Dipping Sharply Lower

By Chris Lau, InvestorPlace Contributor

Nio launched 4 new products and services that will add to its impressive growth rate, making NIO stock look like a good buy if it dips again.

Get out of Nikola Stock While You Still Can

By Chris Lau, InvestorPlace Contributor

NKLA stock traded at nearly $30 temporarily in the last week, giving tired investors one last chance to get out.

7 Pharmaceutical Stocks With Compelling Pipelines

By Chris Lau, InvestorPlace Contributor

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead.

Load More